Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil in Neonates With Down Syndrome to Reduce Pulmonary Vascular Resistance
2021-004600-17Phase 3Terminated
- Sponsor
- RCSI University of Medicine and Health Sciences
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of sildenafil in pulmonary hypertension (PH) and Down syndrome, sponsored by RCSI University of Medicine and Health Sciences. Primary endpoint: Pulmonary vascular resistance echocardiography markers at 2 months. Started Aug 2021; status: terminated.
02
Drugs
sildenafil
03
Conditions
pulmonary hypertension (PH)Down syndrome
Beyond the preview
Go deeper on 2021-004600-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004600-17.